Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fangxiang Wentong prescription for coronary microvascular disease
ChiCTR2200057494Phase 4Recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Jul 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of kuanxiong aerosol in Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Xiyuan Hospital. Primary endpoint: Seattle Angina Questionnaire score. Started Jul 2022; status: recruiting.
02
Drugs
kuanxiong aerosol
03
Conditions
Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR2200057494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057494.